Arcus’s CD73 Inhibitor Could Turn ‘Cold’ Pancreatic Cancer ‘Hot’
There are promising early signals from the novel mechanism, but Arcus’ fortunes remain tied to results from the TIGIT field.
There are promising early signals from the novel mechanism, but Arcus’ fortunes remain tied to results from the TIGIT field.